These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 17901911)

  • 1. Skeletal consequences of thiazolidinedione therapy.
    Grey A
    Osteoporos Int; 2008 Feb; 19(2):129-37. PubMed ID: 17901911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thiazolidinedione-induced skeletal fragility--mechanisms and implications.
    Grey A
    Diabetes Obes Metab; 2009 Apr; 11(4):275-84. PubMed ID: 18671797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis.
    Lecka-Czernik B
    Curr Osteoporos Rep; 2010 Dec; 8(4):178-84. PubMed ID: 20809203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of thiazolidinediones on human bone marrow stromal cell differentiation in vitro and in thiazolidinedione-treated patients with type 2 diabetes.
    Beck GR; Khazai NB; Bouloux GF; Camalier CE; Lin Y; Garneys LM; Siqueira J; Peng L; Pasquel F; Umpierrez D; Smiley D; Umpierrez GE
    Transl Res; 2013 Mar; 161(3):145-55. PubMed ID: 23022285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Do thiazolidinediones harm skeletal integrity?].
    Takeuchi Y
    Clin Calcium; 2008 May; 18(5):650-5. PubMed ID: 18445884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Thiazolidinediones and skeletal health].
    Meier C; Bodmer M; Meier CR; Kraenzlin ME
    Rev Med Suisse; 2009 Jun; 5(207):1309-10, 1312-3. PubMed ID: 19626930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thiazolidinedione safety.
    Kung J; Henry RR
    Expert Opin Drug Saf; 2012 Jul; 11(4):565-79. PubMed ID: 22616948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An insulin-sensitizing thiazolidinedione, which minimally activates PPARγ, does not cause bone loss.
    Fukunaga T; Zou W; Rohatgi N; Colca JR; Teitelbaum SL
    J Bone Miner Res; 2015 Mar; 30(3):481-8. PubMed ID: 25257948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of fractures with glitazones: a critical review of the evidence to date.
    Bodmer M; Meier C; Kraenzlin ME; Meier CR
    Drug Saf; 2009; 32(7):539-47. PubMed ID: 19530741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of thiazolidinediones on skeletal health in women with Type 2 diabetes.
    Schwartz AV; Sellmeyer DE
    Expert Opin Drug Saf; 2008 Jan; 7(1):69-78. PubMed ID: 18171315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thiazolidinedione use and the longitudinal risk of fractures in patients with type 2 diabetes mellitus.
    Habib ZA; Havstad SL; Wells K; Divine G; Pladevall M; Williams LK
    J Clin Endocrinol Metab; 2010 Feb; 95(2):592-600. PubMed ID: 20061432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thiazolidinedione use and bone loss in older diabetic adults.
    Schwartz AV; Sellmeyer DE; Vittinghoff E; Palermo L; Lecka-Czernik B; Feingold KR; Strotmeyer ES; Resnick HE; Carbone L; Beamer BA; Park SW; Lane NE; Harris TB; Cummings SR
    J Clin Endocrinol Metab; 2006 Sep; 91(9):3349-54. PubMed ID: 16608888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antidiabetic therapy effects on bone metabolism and fracture risk.
    Montagnani A; Gonnelli S
    Diabetes Obes Metab; 2013 Sep; 15(9):784-91. PubMed ID: 23368527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thiazolidinediones and fractures: evidence from translating research into action for diabetes.
    Bilik D; McEwen LN; Brown MB; Pomeroy NE; Kim C; Asao K; Crosson JC; Duru OK; Ferrara A; Hsiao VC; Karter AJ; Lee PG; Marrero DG; Selby JV; Subramanian U; Herman WH
    J Clin Endocrinol Metab; 2010 Oct; 95(10):4560-5. PubMed ID: 20631021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PPAR- γ agonist in treatment of diabetes: cardiovascular safety considerations.
    Abbas A; Blandon J; Rude J; Elfar A; Mukherjee D
    Cardiovasc Hematol Agents Med Chem; 2012 Jun; 10(2):124-34. PubMed ID: 22471957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The current role of thiazolidinediones in diabetes management.
    Rizos CV; Kei A; Elisaf MS
    Arch Toxicol; 2016 Aug; 90(8):1861-81. PubMed ID: 27165418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of PPARγ for the osteoblastic differentiation.
    Viccica G; Francucci CM; Marcocci C
    J Endocrinol Invest; 2010; 33(7 Suppl):9-12. PubMed ID: 20938219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Different effects of thiazolidinediones on cardiovascular risk in patients with type 2 diabetes mellitus: pioglitazone versus rosiglitazone.
    Simó R; Rodriguez A; Caveda E
    Curr Drug Saf; 2010 Jul; 5(3):234-44. PubMed ID: 20210732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis.
    Loke YK; Singh S; Furberg CD
    CMAJ; 2009 Jan; 180(1):32-9. PubMed ID: 19073651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thiazolidinediones: effects on insulin resistance and the cardiovascular system.
    Quinn CE; Hamilton PK; Lockhart CJ; McVeigh GE
    Br J Pharmacol; 2008 Feb; 153(4):636-45. PubMed ID: 17906687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.